The potential usefulness of a BCL2 inhibitor (venetoclax) in immature T-ALL is strongly supported by preclinical studies on cell lines and xenograft models [73,74], showing that the drug alters cell proliferation, particularly in cases with an immature phenotype. Here, BCL2 is linked to acute lymphoblastic leukemia.